Back to Newsroom

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

CALGARY, March 4, 2015 /CNW/ – Resverlogix Corp. (TSX:RVX) (the “Company”) today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics.  Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix’s complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company’s Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE. The objective of this collaborative program was to develop quantitative models and identify variables that contribute to drug response, and the incidence of major adverse cardiac events (MACE).

Click here to read the full release